Communiqués Compass Therapeutics, Inc. OTC Markets

Actions

CMPX

US20454B1044

Temps Différé OTC Markets Autres places de cotation 20:59:57 03/11/2021			Varia. 5j.	Varia. 1 janv.
3,55 ^USD	-10,80%		+32,67%	-.--%

28/05	Compass Therapeutics, Inc. annonce des changements de PDG	CI
28/05	Compass Therapeutics, Inc. annonce des changements au sein de sa direction	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference	30/05	AQ
Compass Therapeutics : 2024 Proxy Supplemental	29/05	PU
Compass Therapeutics Announces CEO Transition	28/05	AQ
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024	23/05	AQ
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	14/05	AQ
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update	13/05	AQ
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated	25/04	AQ
Compass Therapeutics : 2024 Proxy	24/04	PU
Compass Therapeutics : Survey of CTX-009 Patient Selection Hypotheses Using Real World Biliary Tract Cancer Data	17/04	PU
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors	16/04	AQ
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference	15/04	AQ
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference	12/04	AQ
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days	10/04	AQ
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting	09/04	AQ
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update	21/03	AQ
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	29/02	AQ
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial	28/02	AQ
Compass Therapeutics Provides Corporate Update	05/01	AQ
Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	09/11	AQ
Compass Therapeutics to Participate in Upcoming Investor Events	07/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Compass Therapeutics, Inc. OTC Markets

Actions

CMPX

US20454B1044

Communiqués

Filtres